<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211124053172N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-01-01</date_registration>
      <primary_sponsor>Kerman University of Medical Sciences</primary_sponsor>
      <public_title>The effect of aromatherapy with lavender and cloves on headache severity caused by spinal anesthesia</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of aromatherapy with lavender and cloves on headache severity caused by spinal anesthesia in patients undergoing urological surgery in Bahonar Hospital in Kerman in 2021-2022</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-12-11</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/60394</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Patients who met the inclusion criteria were selected by convenience sampling method and randomly divided into three groups: aromatherapy with lavender, aromatherapy with cloves and control. To compile a random list, the online software https://www.sealedenvelope.com/simple-randomiser/v1/lists will be used, the size of the blocks will be 6 and the two variables of gender (male / female) and age ( Less than 30 years old) will be considered as classes when creating a random list, Blinding description: At the beginning of the intervention, patients in the intervention group separately in the recovery so that other patients are not exposed to inhalation of the drug by one of the operating room staff who is not present in the study, A sterile gas with 3 drops of fragrance with the desired concentration of 5% (lavender or clove) is impregnated and placed at a distance of 10 cm from the patient's nose and the patient inhales it for 5 minutes This is repeated 8 hours and 24 hours later, and 30 minutes after the second and third interventions, the amount of pain is measured and recorded. The second intervention (8 hours after the operation) and the third (24 hours after the operation) are performed there due to the transfer of the patient to the urology department.In patients in the control group, inhalation of gas impregnated with normal saline is performed and 8 and 24 hours after surgery are examined for the desired variable. In the control group, no intervention is performed.And receive routine care as usual. In addition, all medications received by patients in a total of 24 hours after surgery are recorded in all three intervention and control groups.Also, the environmental conditions, including closing the doors and windows, minimizing the pleasant and unpleasant odors in the ward, are equalized for the three groups. Also, the two intervention groups were placed in separate rooms.</study_design>
      <phase>3</phase>
      <hc_freetext>patients undergoing urological surgery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: At the beginning of the intervention, patients in the intervention group separately in recovery so that other patients are not exposed to inhalation of the drug, a sterile gas with 3 drops of lavender with a concentration of 5% impregnated and placed 10 cm from the patient's nose It is taken and the patient inhales it for 5 minutes, and this is repeated 8 hours and 24 hours later, and 30 minutes after the second and third interventions, the amount of pain is measured and recorded. The second intervention (8 hours after the operation) and the third (24 hours after the operation) are performed there due to the transfer of the patient to the urology department. Intervention 2: Intervention group 2:  At the beginning of the intervention, patients in the intervention group separately in recovery so that other patients are not exposed to inhalation of the drug, a sterile gas with 3 drops of cloves with a concentration of 5% impregnated and placed 10 cm from the patient's nose It is taken and the patient inhales it for 5 minutes, and this is repeated 8 hours and 24 hours later, and 30 minutes after the second and third interventions, the amount of pain is measured and recorded. The second intervention (8 hours after the operation) and the third (24 hours after the operation) are performed there due to the transfer of the patient to the urology department. Intervention 3: Control group: There is no intervention in the control group and they receive routine care as usual.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Atena Samareh Fekri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 22 , Blv jomhouri 13</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>00000000000</zip>
        <telephone>+98 34 3211 3491</telephone>
        <email>atena.samarehfekri@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Atena Samareh Fekri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 22 , Blv jomhouri 13</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>00000000000</zip>
        <telephone>+98 34 3211 3491</telephone>
        <email>atena.samarehfekri@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>No previous history of spinal anesthesia
Classes 1 and 2 based on ASA classification
Lack of blindness and deafness due to the use of visual pain scale
No history of migraine and chronic headache
Lack of sensitivity to aromatic substances
No history of respiratory disease such as asthma, sinus disorders and rhinitis
Do not use aromatherapy for the patient for a week before the intervention
No mental health problems with a doctor's diagnosis
Perform anesthesia by an anesthesiologist with a needle of the same size with just one attempt
No coagulation disorders</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Perform re-spinal anesthesia
Induction of general anesthesia
Having an absolute rest of more than 8 hours
Emergence of skin and respiratory allergies in the patient
Preoperative headache
pregnant women</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>urological surgery</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: At the beginning of the intervention, patients in the intervention group separately in recovery so that other patients are not exposed to inhalation of the drug, a sterile gas with 3 drops of lavender with a concentration of 5% impregnated and placed 10 cm from the patient's nose It is taken and the patient inhales it for 5 minutes, and this is repeated 8 hours and 24 hours later, and 30 minutes after the second and third interventions, the amount of pain is measured and recorded. The second intervention (8 hours after the operation) and the third (24 hours after the operation) are performed there due to the transfer of the patient to the urology department.</i_keyword>
      <i_keyword>Intervention group 2:  At the beginning of the intervention, patients in the intervention group separately in recovery so that other patients are not exposed to inhalation of the drug, a sterile gas with 3 drops of cloves with a concentration of 5% impregnated and placed 10 cm from the patient's nose It is taken and the patient inhales it for 5 minutes, and this is repeated 8 hours and 24 hours later, and 30 minutes after the second and third interventions, the amount of pain is measured and recorded. The second intervention (8 hours after the operation) and the third (24 hours after the operation) are performed there due to the transfer of the patient to the urology department.</i_keyword>
      <i_keyword>Control group: There is no intervention in the control group and they receive routine care as usual.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain score on the VAS scale. Timepoint: Pain measurement at the beginning of the study (before the intervention) and 30 minutes after the second intervention (8 hours after surgery) and the third (24 hours after surgery). Method of measurement: Visual Analog Scale (VAS).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kerman University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-11-08</approval_date>
        <contact_name>Kerman University of Medical Sciences</contact_name>
        <contact_address>campus of Kerman University of Medical Sciences, The beginning of Haft Bagh Alavi axis Kerman Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
